World Journal of
Pharmaceutical and Life Sciences

FORMULATION AND EVALUATION OF LORNOXICAM MICROSPONGE-BASED GEL AS A TRANSDERMAL DRUG DELIVERY SYSTEMS

Mahmoud Mahyoob Alburyhi*, Tawfeek A. A. Yahya, Abdalwali Ahmed Saif and Maged Alwan Noman

ABSTRACT

Microsponges are porous microspheres ranging in size from 5 to 300 micrometers used in a polymeric delivery system. Microsponge may reduce undesired side effects and increase drug stability by boosting drug release. Multiparticulate drug delivery systems are important because they are simple to build and can control drug release in various ways, such as rate control, site control, or both. Drug-entrapped microsponge can be used to make a variety of formulations, including tablets, gels, capsules, powders, lotions, and creams. This microsponge drug delivery technique provides enhanced drug entrapment and stability, allowing for greater formulation flexibility and a significant reduction in unwanted side effects. Lornoxicam (chlortenoxicam), a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties, is available in oral and parenteral formulations. It differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. It is a strong analgesic and anti-inflammatory NSAID as compared to other NSAIDs. The objective of present study was to formulate and evaluate Lornoxicam microsponges using quasi emulsion solvent diffusion technique and Microsponge-Based Gel by using Carbopol and to enhance the release and release of Lornoxicam which is the limitation for preparation in topical forms Also skin delivery (TDDS) is an alternative administration for Lornoxicam that can minimize gastrointestinal (GI) side effects and improve patient compliance. The effects of drug to excipients and physical characteristics of Lornoxicam were investigated. Microsponge-Based Gel containing Lornoxicam and Eudragit® (S100, RS100, E100, L100) were prepared by quasi emulsion solvent diffusion method. The internal phase consisting Eudragit®and glycerol dissolved in dichloromethane, drug is slowly added to polymer solution with continuous stirring for 1h, and then mixture was filtered to separate the microsponges. Production yield, particle size analysis, surface morphology and in-vitro release from the Microsponge-Based Gel was also investigated. In-vitro release study showed that the release rate of the drug has been modified. The formulations were prepared as Microsponge-Based Gel in 0.5%w/w Carbopol and studied physical parameters of Microsponge-Based Gel and evaluated of pH. Microsponge-Based Gel formulation F1 (EudragitE100+Drug) show controlled drug release therefore it can be used to formulation a Microsponge-Based Gel with controlled release profile and it can cover the need of patient of therapeutic concentration all over the day.

[Full Text Article]   [Download Certificate]